Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Organogenesis Holdings Inc (ORGO)

Organogenesis Holdings Inc (ORGO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 486,073
  • Shares Outstanding, K 126,912
  • Annual Sales, $ 482,040 K
  • Annual Income, $ 860 K
  • EBIT $ -8 M
  • EBITDA $ 17 M
  • 60-Month Beta 1.46
  • Price/Sales 1.05
  • Price/Cash Flow 18.07
  • Price/Book 1.88

Options Overview Details

View History
  • Implied Volatility 630.79% (+59.04%)
  • Historical Volatility 54.36%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 630.79% on 02/10/26
  • IV Low 78.96% on 03/24/25
  • Expected Move (DTE 10) 1.23 (31.36%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 70
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 2,206
  • Open Int (30-Day) 1,965
  • Expected Range 2.70 to 5.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.04
  • Growth Rate Est. (year over year) +2,497,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.60 +9.32%
on 01/20/26
4.38 -10.17%
on 02/02/26
-0.28 (-6.65%)
since 01/09/26
3-Month
3.60 +9.32%
on 01/20/26
7.08 -44.47%
on 11/11/25
-2.61 (-39.91%)
since 11/10/25
52-Week
2.61 +50.57%
on 06/03/25
7.08 -44.47%
on 11/11/25
+0.36 (+10.08%)
since 02/10/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors...

ORGO : 3.87 (+1.04%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors...

ORGO : 3.87 (+1.04%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors...

ORGO : 3.87 (+1.04%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors...

ORGO : 3.87 (+1.04%)
Organogenesis Announces Initiation of Biologics License Application for ReNu®

CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product...

ORGO : 3.87 (+1.04%)
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO),...

ORGO : 3.87 (+1.04%)
Organogenesis: Q3 Earnings Snapshot

Organogenesis: Q3 Earnings Snapshot

ORGO : 3.87 (+1.04%)
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...

ORGO : 3.87 (+1.04%)
Organogenesis Applauds CMS’s Significant Step In Payment Reform

CANTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...

ORGO : 3.87 (+1.04%)
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...

ORGO : 3.87 (+1.04%)

Business Summary

Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets.

See More

Key Turning Points

3rd Resistance Point 4.11
2nd Resistance Point 3.99
1st Resistance Point 3.91
Last Price 3.87
1st Support Level 3.71
2nd Support Level 3.60
3rd Support Level 3.52

See More

52-Week High 7.08
Fibonacci 61.8% 5.37
Fibonacci 50% 4.84
Fibonacci 38.2% 4.32
Last Price 3.87
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar